
CX-6258
CAS No. 1202916-90-2
CX-6258( CX6258 | CX 6258 )
Catalog No. M10741 CAS No. 1202916-90-2
A potent, selective, and orally efficacious pan-Pim inhibitor with IC50 of 5/25/16 nM for Pim1/2/3, respectively.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 43 | In Stock |
![]() ![]() |
5MG | 72 | In Stock |
![]() ![]() |
10MG | 115 | In Stock |
![]() ![]() |
25MG | 230 | In Stock |
![]() ![]() |
50MG | 372 | In Stock |
![]() ![]() |
100MG | 531 | In Stock |
![]() ![]() |
200MG | 771 | In Stock |
![]() ![]() |
500MG | Get Quote | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameCX-6258
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective, and orally efficacious pan-Pim inhibitor with IC50 of 5/25/16 nM for Pim1/2/3, respectively.
-
DescriptionA potent, selective, and orally efficacious pan-Pim inhibitor with IC50 of 5/25/16 nM for Pim1/2/3, respectively; exhibits in vitro synergy with chemotherapeutics and robust in vivo efficacy in driven tumor models; also decreases steady state levels and half-life of NKX3.1 protein but not mRNA in prostate cancer cells.Blood Cancer Discontinued.
-
In VitroCX-6258 causes dose dependent inhibition of the phosphorylation of two pro-survival proteins, Bad and 4E-BP1, at the Pim kinase specific sites S112 and S65 and T37/46, respectively.CX-6258 treatment (12 mM, 3 h) treatment diminishes steady-state levels of ectopic NKX3.1 in PC3 cells.CX-6258 treatment results in a significant reduction in NKX3.1 half-life. Western Blot Analysis Cell Line:MV-4-11 human AML cells Concentration:0.1 μM, 1 μM, 10 μM Incubation Time:2 hours Result:Caused dose dependent inhibition of the phosphorylation of two pro-survival proteins, Bad and 4E-BP1, at the Pim kinase specific sites S112 and S65 and T37/46, respectively.
-
In VivoCX-6258 (50-100 mg/kg; p.o; daily; over a period of 21 days) exhibits robust in vivo efficacy in two Pim kinases driven tumor models. Animal Model:Nude mice, MV-4-11 xenograft modelsDosage:50 mg/kg, 100 mg/kg Administration:Oral administration; once daily; over a period of 21 days Result:Exhibited dose dependent efficacy, with a 50 mg/kg dose producing 45% tumor growth inhibition (TGI) and a 100 mg/kg dose producing 75% TGI.
-
SynonymsCX6258 | CX 6258
-
PathwayJAK/STAT Signaling
-
TargetPim
-
RecptorPim1| Pim2| Pim3
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1202916-90-2
-
Formula Weight461.9401
-
Molecular FormulaC26H24ClN3O3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESCN1CCCN(CC1)C(=O)C2=CC=CC(=C2)C3=CC=C(O3)/C=C/4\C5=C(C=CC(=C5)Cl)NC4=O
-
Chemical Name2H-Indol-2-one, 5-chloro-3-[[5-[3-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]phenyl]-2-furanyl]methylene]-1,3-dihydro-, (3E)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Haddach M, et al. ACS Med Chem Lett. 2011 Dec 27;3(2):135-9.
2. Padmanabhan A, et al. J Cell Biochem. 2013 May;114(5):1050-7.
3. Rebello RJ, et al. Clin Cancer Res. 2016 Nov 15;22(22):5539-5552.
molnova catalog



related products
-
INCB053914
INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.
-
PIM-447 dihydrochlor...
A highly potent and selective inhibitor of pan-Pim with IC50s of 6/18/9 pM for Pim/1/2/3 respectively.
-
GDC-0339
GDC-0339 is a novel small molecule pan-Pim kinase inhibitor that was discovered as a potential treatment for multiple myeloma.